Comparative Pharmacology
Head-to-head clinical analysis: AMITRIPTYLINE HYDROCHLORIDE versus SURMONTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMITRIPTYLINE HYDROCHLORIDE versus SURMONTIL.
AMITRIPTYLINE HYDROCHLORIDE vs SURMONTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits reuptake of serotonin and norepinephrine, leading to increased concentrations at synaptic cleft; also blocks histamine H1, alpha-1 adrenergic, and muscarinic cholinergic receptors.
Tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin, with anticholinergic, antihistaminergic, and alpha-adrenergic blocking properties.
Oral: 25-150 mg daily in divided doses or as a single bedtime dose; maximum 300 mg/day.
50-75 mg/day orally in divided doses, increase gradually to 150-300 mg/day. Maximum 300 mg/day. Single bedtime dose may be used for maintenance (50-150 mg).
None Documented
None Documented
Terminal elimination half-life is 15-35 hours (range 9-46 hours); clinical context: steady-state concentrations achieved within 7-10 days; may be prolonged in elderly, hepatic impairment, or CYP2D6 poor metabolizers.
11-27 hours (mean approximately 20 hours) for the parent drug; the active metabolite desmethyltrimipramine has a half-life of 15-30 hours. Steady-state is achieved within 5-7 days.
Primarily renal (approximately 30-50% as unchanged drug and metabolites, mainly glucuronide conjugates and hydroxylated metabolites). Fecal excretion accounts for <5%. Enterohepatic recirculation may occur.
Renal excretion of metabolites accounts for approximately 70-80% of elimination, with about 20-30% excreted in feces via biliary elimination. Unchanged drug in urine is less than 5%.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant